Mekinist (trametinib) — Medica
Non-Small Cell Lung Cancer
Initial criteria
- Patient has recurrent, advanced, or metastatic disease
- Patient has BRAF V600 mutation-positive disease
- The medication is prescribed in combination with Tafinlar (dabrafenib)
Approval duration
1 year